Quantcast

Industry news that matters to you.  Learn more

New Data From Phase 2a Oral Mucositis Study Presented at American Association for Cancer Research Conference

SciClone Pharmaceuticals, Inc. today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer. The Company believes that the discovery of these gene clusters may assist in providing the framework for effectively identifying those patients most likely to respond to SCV-07 in future clinical trials based on their individual genomic profile or gene signature.